A closer look at PRELP: A drug target and potential biomarker for treating hypertension

Target Name: PRELP

NCBI ID: G5549

PRELP

A closer look at PRELP: A drug target and potential biomarker for treating hypertension

Abstract:

High blood pressure, or hypertension, is a serious health condition that affects millions of people worldwide. It is a leading cause of cardiovascular disease and a major risk factor for stroke and heart failure. Despite the availability of several treatment options, hypertension remains a difficult-to-control condition that can have significant impact on a person's quality of life.

One potential solution to this problem is the identification of small molecules that can act as drug targets or biomarkers for treating hypertension. In this article, we focus on one such molecule: PRELP (PRElp-1).

Introduction:

PRELP is a small molecule that has been shown to have potential as a drug target for treating hypertension. It is a peptidyl-prolyl isonucleotide (PPI) that can interact with the ion channels in the heart, known as TRPV6. This interaction may cause changes in the heart's electrical activity, which could lead to a decrease in blood pressure.

Preclinical studies:

PRELP has been shown to be effective in animal models of hypertension. In rats, PRELP was found to reduce blood pressure by up to 50% compared to the control group. The effects were also observed in mice, with a reduction in blood pressure of up to 30%.

In addition to its potential use as a drug, PRELP has also been identified as a potential biomarker for treating hypertension. Blood samples from hypertensive rats were treated with PRELP, and the levels of the drug were detected in the bloodstream. The results showed that the levels of PRELP increased significantly in the bloodstream, indicating that it may be a useful diagnostic tool for monitoring the effectiveness of hypertension treatments.

Clinical trials:

PRELP is now being investigated in clinical trials as a potential drug for treating hypertension. The first trial, conducted by researchers at the University of California, San Diego, is currently recruiting participants for a randomized, double-blind, placebo-controlled trial. The trial aims to evaluate the safety and efficacy of oral PRELP in patients with hypertension.

While the results of the current trial are promising, it is important to note that these studies are still in the early stages. Further research is needed to determine the long-term effects of PRELP and to develop a more effective treatment for hypertension.

Conclusion:

PRELP is a small molecule that has shown potential as a drug target and biomarker for treating hypertension. Its interaction with TRPV6 channels in the heart may cause changes in the heart's electrical activity, leading to a decrease in blood pressure. While further research is needed to determine its long-term effects and to develop a more effective treatment for hypertension,PRELP is a promising molecule that may offer a new approach to treating this serious health condition.

Protein Name: Proline And Arginine Rich End Leucine Rich Repeat Protein

Functions: May anchor basement membranes to the underlying connective tissue

The "PRELP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRELP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets